Dacomitinib Comparable to Erlotinib for EGFR+ Advanced Lung Cancer

Share this content:
Dacomitinib is an active agent with comparable efficacy to erlotinib in patients with non-small cell lung cancer.
Dacomitinib is an active agent with comparable efficacy to erlotinib in patients with non-small cell lung cancer.

Dacomitinib is an active agent with comparable efficacy to erlotinib in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC), particularly in those with exon 19 deletion, a study published online ahead of print in the journal Annals of Oncology has shown.1

Although the irreversible EGFR inhibitors, like dacomitinib, have demonstrated efficacy in patients with NSCLC with activating EGFR mutations, it is unclear whether they are superior to reversible inhibitors, like erlotinib. Therefore, researchers sought to conduct a pooled analysis of 2 randomized trials to compare the efficacy of dacomitinib with erlotinib.

For the study, researchers analyzed data from 129 patients with locally advanced/metastatic NSCLC and any EGFR mutation. Patients were only included if they had progressed on or after 1 or 2 chemotherapy regimens prior to dacomitinib or erlotinib. Of those, 101 had activating mutations in exon 19 or 21.

Results showed that among patients with exon 19 or 21 mutations, median progression-free survival was 14.6 months (95% CI, 9.0 - 18.2) with dacomitinib and 9.6 months (95% CI, 7.4 - 12.7) with erlotinib (HR, 0.717; 95% CI, 0.458 - 1.124; P = .146).

Researchers found that median overall survival was 26.6 months (95% CI, 21.6 - 41.5) with dacomitinib vs 23.2 months (95% CI, 16.0 - 31.8) with erlotinib (HR, 0.737; 95% CI, 0.431 - 1.259; P = .265).

RELATED: Adjuvant EGFR TKIs May Enhance DFS in NSCLC

In terms of safety, dacomitinib was associated with a higher incidence of diarrhea and mucositis than with erlotinib in both studies.

The investigators noted that an ongoing phase 3 trial will compare dacomitinib with gefitinib in the first-line treatment setting of patients with NSCLC and common activating EGFR mutations.

Reference

  1. Ramalingam SS, O'Byrne K, Boyer M, et al. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials [published online ahead of print January 13, 2016]. Ann Oncol. doi: 10.1093/annonc/mdv593.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs